Piper Sandler Maintains Neutral on TELA Bio, Lowers Price Target to $1
Benzinga Newsdesk 7 months ago
NewsPrice TargetAnalyst Ratings
Piper Sandler analyst Matt O'Brien maintains TELA Bio (NASDAQ:TELA) with a Neutral and lowers the price target from $1.25 to $1.
Piper Sandler analyst Matt O'Brien maintains TELA Bio (NASDAQ:TELA) with a Neutral and lowers the price target from $1.25 to $1.